EUVIMEDEUVIMED entdecken
Klinische Studie (Phase I)Open Access · CC BY 4.0

Effects of Quinidine or Rifampin Co‐administration on the Single‐Dose Pharmacokinetics and Safety of Rilzabrutinib (PRN1008) in Healthy Participants

Christian Rask-Madsen, Suresh Katragadda, Mengyao Li, Sibel Ucpinar, Leslie Chinn, Puneet Arora, Patrick Smith

Clinical Pharmacology in Drug Development · 2024

DOI: 10.1002/cpdd.1404 ↗

Kurz gefasst

Klinische Studie (Phase I) in der Zeitschrift Clinical Pharmacology in Drug Development, 2024. Verfasst von Christian Rask-Madsen und 6 weiteren Autor:innen. Beteiligte Einrichtung: Translational Medicine and Clinical Pharmacology, Sanofi, Cambridge, MA, USA. Hauptthemen laut MEDLINE: Rifampin, Quinidine, Drug Interactions, Healthy Volunteers. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

This open‐label, phase 1 study was conducted with healthy adult participants to evaluate the potential drug‐drug interaction between rilzabrutinib and quinidine (an inhibitor of P‐glycoprotein [P‐gp] and CYP2D6) or rifampin (an inducer of CYP3A and P‐gp). Plasma concentrations of rilzabrutinib were measured after a single oral dose of rilzabrutinib 400 mg administered on day 1 and again, following a wash‐out period, after co‐administration of rilzabrutinib and quinidine or rifampin. Specifically, quinidine was given at a dose of 300 mg every 8 hours for 5 days from day 7 to day 11 (N = 16) while rifampin was given as 600 mg once daily for 11 days from day 7 to day 17 (N = 16) with rilzabrutinib given in the morning of day 10 (during quinidine dosing) or day 16 (during rifampin dosing). Quinidine had no significant effect on rilzabrutinib pharmacokinetics. Rifampin decreased rilzabrutinib exposure (the geometric mean of C max and AUC 0‐∞ decreased by 80.5% and 79.5%, respectively). Single oral doses of rilzabrutinib, with or without quinidine or rifampin, appeared to be well tolerated. These findings indicate that rilzabrutinib is a substrate for CYP3A but not a substrate for P‐gp.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

RifampinQuinidineDrug InteractionsHealthy VolunteersArea Under CurveHumansAdultMaleFemaleYoung AdultMiddle AgedCytochrome P-450 CYP3A InducersCytochrome P-450 CYP3AATP Binding Cassette Transporter, Subfamily B, Member 1Administration, OralPyrimidines

Stichwörter der Autor:innen

Bruton's tyrosine kinaseCYP3Adrug‐drug interactionspharmacokineticsquinidinerifampinrilzabrutinib

Substanzen

RifampinQuinidineCytochrome P-450 CYP3A InducersCytochrome P-450 CYP3AATP Binding Cassette Transporter, Subfamily B, Member 1Pyrimidines

Autor:innen und Institutionen

  • Translational Medicine and Clinical Pharmacology, Sanofi, Cambridge, MA, USA.
  • Department of Pharmacokinetics, Dynamics and Metabolism, Sanofi, Cambridge, MA, USA.
  • Department of Pharmacokinetics, Dynamics and Metabolism, Sanofi, Bridgewater, NJ, USA.
  • Department of Clinical, Inflammation and Immunology, Sanofi, South San Francisco, CA, USA.
  • Integrated Drug Development, Certara, Parsippany, NJ, USA.

Zitieren

APA

Rask-Madsen, C., Katragadda, S., Li, M., Ucpinar, S., Chinn, L., Arora, P., & Smith, P. (2024). Effects of Quinidine or Rifampin Co‐administration on the Single‐Dose Pharmacokinetics and Safety of Rilzabrutinib (PRN1008) in Healthy Participants. Clinical Pharmacology in Drug Development. https://doi.org/10.1002/cpdd.1404

Vancouver

Rask-Madsen C, Katragadda S, Li M, Ucpinar S, Chinn L, Arora P, et al. Effects of Quinidine or Rifampin Co‐administration on the Single‐Dose Pharmacokinetics and Safety of Rilzabrutinib (PRN1008) in Healthy Participants. Clinical Pharmacology in Drug Development. 2024. doi:10.1002/cpdd.1404

BibTeX
@article{RaskMadsen2024,
  author = {Rask-Madsen, Christian and Katragadda, Suresh and Li, Mengyao and Ucpinar, Sibel and Chinn, Leslie and Arora, Puneet and Smith, Patrick},
  title = {Effects of Quinidine or Rifampin Co‐administration on the Single‐Dose Pharmacokinetics and Safety of Rilzabrutinib (PRN1008) in Healthy Participants},
  journal = {Clinical Pharmacology in Drug Development},
  year = {2024},
  doi = {10.1002/cpdd.1404}
}
Kostenlos starten →